A Phase 1/2a, Randomized, Double-blind, Placebo-controlled Study of Ascending Doses of WVE-007 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults Living With Overweight or Obesity

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) . Part A is a single ascending dose study in adults living with overweight and obesity. The Part B of the study is a repeat dose administration in two adult populations: Pre Type 2 diabetes (Pre T2D) and Type 2 Diabetes (T2D) in adults who are affected by obesity.

Start Date31 Jan 2025

Sponsor / Collaborator

Wave Life Sciences Ltd.

100 Clinical Results associated with WVE-007

100 Translational Medicine associated with WVE-007

100 Patents (Medical) associated with WVE-007

Literatures (Medical) associated with WVE-007

01 Apr 2020·GutQ1 · MEDICINE

Adeno-associated virus in the liver: natural history and consequences in tumour development

Q1 · MEDICINE

Article

Author: Valerie Paradis ; Laurence Chiche ; Guillaume Morcrette ; Paulette Bioulac-Sage ; Julien Calderaro ; Iadh Mami ; Shalini Datta ; Theo Z Hirsch ; Jean-Frederic Blanc ; Jessica Zucman-Rossi ; Sandrine Imbeaud ; Catherine Guettier ; Alexis Laurent ; Eric Letouze ; Giuliana Amaddeo ; Stefano Caruso ; Laurent Possenti ; Tiziana La Bella ; Camille Peneau ; Jean-Charles Nault ; Quentin Bayard

Objective:

Adeno-associated virus (AAV) is a defective mono-stranded DNA virus, endemic in human population (35%–80%). Recurrent clonal AAV2 insertions are associated with the pathogenesis of rare human hepatocellular carcinoma (HCC) developed on normal liver. This study aimed to characterise the natural history of AAV infection in the liver and its consequence in tumour development.

Design:

Viral DNA was quantified in tumour and non-tumour liver tissues of 1461 patients. Presence of episomal form and viral mRNA expression were analysed using a DNAse/TaqMan-based assay and quantitative RT-PCR. In silico analyses using viral capture data explored viral variants and new clonal insertions.

Results:

AAV DNA was detected in 21% of the patients, including 8% of the tumour tissues, equally distributed in two major viral subtypes: one similar to AAV2, the other hybrid between AAV2 and AAV13 sequences. Episomal viral forms were found in 4% of the non-tumour tissues, frequently associated with viral RNA expression and human herpesvirus type 6, the candidate natural AAV helper virus. In 30 HCC, clonal AAV insertions were recurrently identified in CCNA2 , CCNE1 , TERT , TNFSF10 , KMT2B and GLI1 / INHBE . AAV insertion triggered oncogenic overexpression through multiple mechanisms that differ according to the localisation of the integration site.

Conclusion:

We provided an integrated analysis of the wild-type AAV infection in the liver with the identification of viral genotypes, molecular forms, helper virus relationship and viral integrations. Clonal AAV insertions were positive selected during HCC development on non-cirrhotic liver challenging the notion of AAV as a non-pathogenic virus.

JOURNAL OF INFECTIOUS DISEASES

Specific Biomarkers Differentiate Cerebral Malaria From Other Causes of Coma in African Children

Article

Author: Mwangi, Shaban ; Rodriguez, Ana ; Abdi, Abdirahman I ; Gomes, Claudia

Abstract:

Background:

Cerebral malaria (CM) is a serious complication of Plasmodium falciparum malaria that causes coma and, frequently, death. In malaria-endemic settings, a large percentage of the population presents with incidental P falciparum malaria parasitemia. In the absence of specific biomarkers for CM, when these individuals suffer from bacterial or viral infections causing coma, they are frequently misdiagnosed with CM.

Methods:

We have tested the specificity for CM of 2 candidate biomarkers for severe malaria, angiopoietin-like 4 (ANGPTL4) and inhibin-βE (INHBE), which are secreted by endothelial cells in response to P falciparum–infected erythrocytes. The levels of these biomarkers were determined retrospectively in the plasma of a cohort of 379 Kenyan children including cases of severe malaria caused by CM, respiratory distress, or severe anemia, as well as cases of nontraumatic coma of unknown cause.

Results:

ANGPTL4 and INHBE showed high specificity for severe malaria, including CM (area under the curve [AUC] 0.82), respiratory distress (AUC 0.86), and severe anemia (AUC 0.85), when compared to acute nontraumatic coma of nonmalarial etiology. Specificity was further increased when the biomarkers were used in combination with platelet levels (AUC 0.96). ANGPTL4 and INHBE are also predictors of death by CM (AUC 0.85).

Conclusions:

ANGPTL4 and INHBE could be developed as a diagnostic tool for the differentiation of comatose patients with CM from other causes of coma.

Biomolecules and biomedicine

Mechanistic insights into Y-Box binding protein-1 mediated regulation of lipid metabolism and oxidative stress in NAFLD via INHBE/TNF-β pathway

Article

Author: Wang, Rui ; Ke, Xiquan ; Ren, Zhi ; Wei, Jun ; Ma, Zhenzeng

Nonalcoholic fatty liver disease (NAFLD) is a prevalent liver disorder that has emerged as a significant public health concern. This study aimed to investigate the mechanisms by which Y-box binding protein-1 (YB1) knockdown influences lipid metabolism and oxidative stress in palmitic acid (PA)-induced NAFLD LO2 cells. The expression of YB1 was analyzed using the GSE89632 dataset from the Gene Expression Omnibus (GEO) database. RNA sequencing was performed, followed by Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses, and protein-protein interaction (PPI) network analyses to identify differentially expressed genes (DEGs). Quantitative real-time PCR (QRT-PCR), Western blotting, flow cytometry, and various biochemical assays were used to evaluate gene expression, lipid accumulation, and oxidative stress. Our results demonstrated that YB1 is highly expressed in NAFLD. RNA sequencing revealed 798 DEGs between the shCtrl and shYB1 groups, with 190 genes upregulated and 608 genes downregulated. Notably, we observed an increase in Inhibin beta E (INHBE) expression, while EGR1, GDF15, NUPR1, and FOSB were decreased in NAFLD LO2 cells. YB1 knockdown, particularly when combined with INHBE suppression, significantly enhanced cell viability, improved lipid metabolism, and reduced reactive oxygen species (ROS) accumulation and malondialdehyde (MDA) content. The downstream mechanism was primarily associated with TNF-β signaling. Specifically, we observed decreased levels of TGF-β1, p-Smad2, and p-Smad3 following YB1 and INHBE knockdown. Furthermore, INHBE overexpression reversed the beneficial effects induced by YB1 knockdown. In conclusion, YB1 knockdown improves lipid metabolism and reduces oxidative stress in NAFLD LO2 cells, largely through the INHBE/TNF-β signaling pathway. These findings provide valuable insights into novel therapeutic strategies for managing NAFLD.

News (Medical) associated with WVE-007

07 Jul 2026

·ir.wavelifesciences.com

Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation

CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), has obtained the requisite shareholder approval required in connection with its proposed redomiciliation (“Redomiciliation”) to the United States by way of the implementation of a statutory procedure known as a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore (the “Scheme of Arrangement”). The Scheme of Arrangement remains subject to approval by the High Court of the Republic of Singapore (the “Singapore Court”). Wave has made an application to the Singapore Court to approve the Scheme of Arrangement, as filed in HC/SUM 2058/2026 in HC/OA 434/2026 in the Singapore Court on July 1, 2026 (Singapore Time), and the application has been directed to be heard before the Singapore Court on July 14, 2026 at 2:30 pm (Singapore Time), at Chamber 2A of the Supreme Court of Singapore at 1 Supreme Court Lane, Singapore 178879. The Singapore Court has directed that any affidavits in response to the application must be submitted to the Singapore Court by 4:00 pm (Singapore Time) on July 8, 2026, and that any written submissions and bundles of authorities must be filed with and tendered to the Singapore Court by 4:00 pm (Singapore Time) on July 10, 2026. A copy of the materials filed with the application and the related directions provided by the Singapore Court will be made available under the Corporate Governance section of our Investor Relations website. About Wave Life Sciences Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn. Cautionary Note Regarding Forward-Looking Statements Some of the statements included in this announcement may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, in particular, statements about our expectations regarding the change of the parent company of the group from a Singapore company to a Delaware corporation. These statements include, but are not limited to, statements that address our expected future business and statements about the Redomiciliation and other statements identified by words such as “will”, “expect”, “believe”, “anticipate”, “estimate”, “should”, “intend”, “plan”, “potential”, “predict”, “project”, “aim”, and similar words, phrases or expressions. These forward-looking statements are based on current expectations and beliefs of the management of Wave Life Sciences, as well as assumptions made by, and information currently available to, such management, current market trends and market conditions and involve risks and uncertainties, many of which are outside Wave Life Sciences’ and management’s control, and which may cause actual results to differ materially from those contained in forward looking statements. Accordingly, you should not place undue reliance on such statements. Particular uncertainties that could materially affect future results include risks associated with the Redomiciliation, including our ability to obtain shareholder and Singapore High Court approvals and satisfy other closing conditions to the completion of the Redomiciliation within the expected timeframe or at all; our ability to realize the expected benefits from the Redomiciliation; the occurrence of difficulties or material timing delays in connection with the Redomiciliation, including any unanticipated costs in connection therewith; any delays, challenges and expenses associated with receiving governmental and regulatory approvals; changes in tax laws, tax treaties or tax regulations or the interpretation or enforcement thereof by the tax authorities in Singapore, the United States and other jurisdictions following the Redomiciliation; our critical accounting policies; the ability of our preclinical studies to produce data sufficient to support the filing of global clinical trial applications and the timing thereof; our ability to continue to build and maintain the company infrastructure and personnel needed to achieve our goals; the clinical results and timing of our programs, which may not support further development of our product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; our effectiveness in managing current and future clinical trials and regulatory processes; the success of our platform in identifying viable candidates; the continued development and acceptance of nucleic acid therapeutics as a class of drugs; our ability to demonstrate the therapeutic benefits of our stereopure candidates in clinical trials, including our ability to develop candidates across multiple therapeutic modalities; our ability to obtain, maintain and protect intellectual property; our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties; our ability to fund our operations and to raise additional capital as needed; competition from others developing therapies for similar uses; and any impacts on our business as a result of or related to any local and global health epidemics, geopolitical conflicts, global economic uncertainty, the impact of tariffs and changes in economic policies, volatility in inflation, volatility in interest rates or market disruptions on our business. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are set forth in our definitive proxy statement filed on May 7, 2026 and our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the other documents that we file with the SEC, including under the heading “Risk Factors” in our most recent Annual Report on Form 10-K. You may obtain copies of these documents as described under the heading “Additional Information and Where to Find It.” Our filings with the Securities and Exchange Commission (“SEC”), which you may obtain without charge at the SEC’s website at http://www.sec.gov, discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no intent or obligation to publicly update or revise any of these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Investors: James Salierno Director, Investor Relations +1 617-949-4043 InvestorRelations@wavelifesci.com Media: Katie Sullivan Senior Director, Corporate Communications +1 617-949-2936 MediaRelations@wavelifesci.com

24 Jun 2026

·www.biospace.com

Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases

In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while maintaining muscle; data continue to support once or twice-yearly dosing Phase 2a portion in individuals with higher BMI and body fat, with and without type 2 diabetes, includes multiple assessments to inform further development of WVE-007 in obesity as well as MASH, type 2 diabetes, and cardiovascular disease Wave is on track to initiate additional Phase 2 trials in 2H 2026 evaluating WVE-007 in combination with incretins and as post-incretin maintenance CAMBRIDGE, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced it has initiated the Phase 2a multidose portion of the INLIGHT™ trial, a placebo-controlled (3:1) study evaluating WVE-007, an investigational GalNAc-siRNA, as monotherapy in individuals living with obesity with high BMI (35-50 kg/m 2 ) and comorbidities. The INLIGHT trial also includes an ongoing Phase 1 single dose portion investigating WVE-007 in otherwise healthy individuals living with overweight or obesity, with an average BMI of 32 kg/m 2 . In this portion of the trial, at six months of follow-up, a single 240 mg dose of WVE-007 continued to drive clinically meaningful reductions in visceral fat (-14%; p<0.05), total fat (-5%), and waist circumference (-3%). WVE-007 continues to be generally safe and well tolerated up to 600 mg and data support the potential for once or twice-yearly dosing. The Phase 2a portion of the INLIGHT trial is expected to demonstrate further body composition improvements, including greater fat loss with preserved muscle, weight loss, and improved biomarkers of cardiometabolic health. “We have strong conviction in WVE-007’s potential to redefine obesity treatment and long-term cardiometabolic health, with early clinical results demonstrating a 14% visceral fat reduction without muscle loss six months following a single dose. The link between visceral fat and cardiometabolic outcomes is well established and further validated by a recent publication which demonstrated that for every 10% reduction in visceral fat, an individual’s risk of developing type 2 diabetes was 28% lower even a decade later,” 1 said Christopher Wright, MD, PhD, Chief Medical Officer at Wave Life Sciences. “Importantly, this next portion of the INLIGHT trial will evaluate a patient population with higher BMI and greater adiposity, consistent with Phase 2 and Phase 3 obesity trials. Given WVE-007’s mechanism of targeted lipolysis, we believe this portion of the study can deliver even more pronounced improvements in body composition and we expect to gain a clearer understanding of WVE-007's potential to drive clinically meaningful weight loss, reduce fat, and preserve muscle, while informing its broader role in metabolic care.” The Phase 2a portion of the INLIGHT trial is expected to enroll participants across the U.S. and Europe and includes multiple assessments over a 12-month period, including body weight, waist circumference, body composition (MRI and DEXA), liver fat (MRI-PDFF), HbA1c, and lipid levels. The results will inform further development of WVE-007 in obesity, as well as MASH, type 2 diabetes, and cardiovascular disease. Wave also expects to initiate new clinical trials evaluating WVE-007 as an incretin add-on and as post-incretin maintenance in the second half of 2026. About WVE-007 WVE-007 is an investigational GalNAc-siRNA that utilizes Wave’s best-in-class proprietary oligonucleotide chemistry and the company’s Stereopure interfering Nucleic Acid (SpiNA) next generation siRNA design. WVE-007 is designed to silence INHBE mRNA, an obesity target with strong evidence from human genetics. Individuals who have a protective loss-of-function variant in one copy of the INHBE gene have a healthier body composition and cardiometabolic profile, including less visceral fat and lower risk of type 2 diabetes or cardiovascular disease. In preclinical models, INHBE GalNAc-siRNA led to adipocyte shrinkage, fewer pro-inflammatory macrophages, less fibrosis, and improved insulin sensitivity in visceral adipose tissue, supporting potential for metabolic improvement. As an add-on to semaglutide, Wave’s GalNAc-siRNA doubled weight loss in mice and prevented weight regain upon cessation of semaglutide. About the INLIGHT™ Clinical Trial The INLIGHT trial is an ongoing randomized, placebo-controlled (3:1) study that includes a Phase 1, single-ascending dose portion in otherwise healthy individuals living with overweight or obesity. This portion is designed to assess safety, tolerability, pharmacokinetics, and Activin E target engagement. The INLIGHT trial is currently ongoing at multiple trial sites, including in the U.S. A Phase 2a portion of the INLIGHT trial is evaluating multiple WVE-007 doses in individuals with high BMI, with and without type 2 diabetes, and will assess metabolic and body composition improvements as well as weight loss. About Wave Life Sciences Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave's PRISM® platform combines multiple RNA medicines modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit and follow Wave on X and LinkedIn . Forward-Looking Statements This press release contains forward-looking statements concerning our goals, beliefs, expectations, strategies, objectives and plans, and other statements that are not necessarily based on historical facts, including statements regarding the following, among others: the anticipated initiation, site activation, patient recruitment, patient enrollment, dosing, generation and reporting of data and/or completion of our ongoing and anticipated Phase 2 portions of our INLIGHT clinical trial and the timing and announcement of such events; our expectations to initiate new clinical trials evaluating WVE-007 as an incretin add-on and as post-incretin maintenance, and the expected results and timing thereof; our understanding of the dose levels and dosing frequency for WVE-007; our understanding of the safety pro WVE-007; the potential of WVE-007’s mechanism (INHBE GalNAc-siRNA) as a meaningful and differentiated therapeutic approach for obesity as well as the potential to develop WVE-007 for other indications, including MASH, type 2 diabetes, and cardiovascular disease; the protocol, design and endpoints of the Phase 2a portion of our INLIGHT clinical trial; the future performance and results of WVE-007 in the Phase 2a portion of our INLIGHT clinical trial, including our expectations that there will be even greater improvements in body composition in individuals with higher BMI, visceral fat and body fat at baseline, with and without type 2 diabetes; the potential benefits of our toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), compared to others; the benefits of RNA medicines generally; and the potential for certain of our programs to be best-in-class. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual results to differ materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in Wave’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances. Contact: Kate Rausch VP, Corporate Affairs and Investor Relations +1 617-949-4827 Investors: James Salierno Director, Investor Relations +1 617-949-4043 InvestorRelations@wavelifesci.com Media : Katie Sullivan Senior Director, Corporate Communications +1 617-949-2936 MediaRelations@wavelifesci.com 1 Klein, Hadar, Liav Alufer, Dana Tamar Goldberg Toren, et al. Circulation , 2026 June 2. "Lifestyle-Induced Visceral Fat Loss as a Key Target for Durable Cardiometabolic Health: MRI-Assessed 5- and 10-Year Follow-Up After 2 Clinical Trials."

Phase 2Clinical ResultPhase 1Phase 3

01 Jun 2026

·www.globenewswire.com

Wave Life Sciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave’s management team are scheduled to participate in two upcoming investor conferences in June. 2026 Jefferies Global Healthcare ConferenceDate: Wednesday, June 3, 2026 Details: Paul Bolno, MD, MBA, President and CEO, will participate in an analyst-led fireside chat at 10:30 a.m. ET Goldman Sachs 47th Annual Global Healthcare ConferenceDate: Monday, June 8, 2026 Details: Dr. Bolno will participate in an analyst-led fireside chat at 8:00 a.m. ET Live webcasts of the presentations can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Replays of these presentations will be archived and available on the site for a limited time following the event. About Wave Life SciencesWave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn. Contact:Kate RauschVP, Corporate Affairs and Investor Relations+1 617-949-4827Investors:James SaliernoDirector, Investor Relations+1 617-949-4043InvestorRelations@wavelifesci.com Media:Katie SullivanSenior Director, Corporate Communications+1 617-949-2936MediaRelations@wavelifesci.com

100 Deals associated with WVE-007

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Obesity	Phase 2	Moldova	Wave Life Sciences Ltd.	31 Jan 2025
Obesity	Phase 2	Romania	Wave Life Sciences Ltd.	31 Jan 2025
Obesity	Phase 2	United Kingdom	Wave Life Sciences Ltd.	31 Jan 2025
Metabolic Diseases	Preclinical	United States	Wave Life Sciences Ltd.	20 Aug 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06842186 (INLIGHT, ADA2026)	Phase 1	Overweight \| Obesity	56	WVE-007 240 mg	gmpjzehzkb(zqfxefwlzm) = Robust, dose-dependent, and durable target engagement (TE) was demonstrated: on Day 29, the mean reduction in Activin E from baseline was 56% for 75 mg WVE-007 (n=8), 75% for 240 mg (n=24), and 85% for 400 mg (n=24). In the 240 mg WVE-007 group, mean Activin E reductions of >75% were maintained to at least Day 85, the last available time point. gwhrlbhubq (apeiatfvmh ) View more	Positive	20 Jun 2026
				Placebo
NCT06842186 (INLIGHT, Company_Website) Manual	Phase 1	Obesity	32	WVE-007 240 mg	hyrsdjyvzw(odcfdfvhln) = ltrfipqnfa nxdnatugak (epuuwuumwx ) View more	Positive	08 Dec 2025
				Placebo	hyrsdjyvzw(odcfdfvhln) = gyeyzitjos nxdnatugak (epuuwuumwx ) View more
NCT06842186 (INLIGHT, NEWS) Manual	Phase 2	Obesity	-	WVE-007 75 mg	uesuadfdrk(otjtjsivne) = lbvqohphfc bjrhgtkfpw (cftvroplgn )	Positive	29 Oct 2025
				WVE-007 240 mg	uesuadfdrk(otjtjsivne) = vxccxmlxdu bjrhgtkfpw (cftvroplgn )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

WVE-007

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation